Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Br J Dermatol ; 165(2): 255-62, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21410663

ABSTRACT

Mismatches between skin pigmentation and modern lifestyle continue to challenge our naked skin. One of our responses to these challenges is the development and use of sunscreens. The management of sunscreens has to balance their protective effect against erythema, photocarcinogenesis and photoageing owing to the potential toxicity of the ultraviolet (UV) filters for humans and the environment. The protection against UV radiation offered by sunscreens was recently standardized in the European Union (EU) based on international harmonization of measurement techniques. Four different categories of sun protection have been implemented along with recommendations on how to use sunscreen products in order to obtain the labelled protection. The UV filters in sunscreens have long been authorized for use by the EU authority on the basis of data from studies on acute toxicity, subchronic and chronic toxicity, reproductive toxicity, genotoxicity, photogenotoxicity, carcinogenicity, irritation, sensitization, phototoxicity and photosensitization as well as on environmental aspects. New challenges with respect to the safety of UV filters have arisen from the banning of animal experiments for the development of cosmetics. Future debates on sunscreens are likely to focus on nanoparticles and environmental issues, along with motivation campaigns to persuade consumers to protect their skin. However, more efficient sunscreen use will also continue to raise questions on the benefit in preventing vitamin D synthesis in the skin induced by sunlight.


Subject(s)
Sunburn/prevention & control , Sunscreening Agents/adverse effects , Carcinoma, Squamous Cell/chemically induced , Carcinoma, Squamous Cell/prevention & control , Drug Labeling/legislation & jurisprudence , Drug Monitoring , Environmental Pollution/prevention & control , Humans , Keratosis, Actinic/chemically induced , Keratosis, Actinic/prevention & control , Legislation, Drug , Life Style , Melanoma/chemically induced , Melanoma/prevention & control , Patient Compliance , Patient Education as Topic , Skin Neoplasms/chemically induced , Skin Neoplasms/prevention & control , Sunscreening Agents/standards , Treatment Outcome , Vitamin D/antagonists & inhibitors
2.
J Eur Acad Dermatol Venereol ; 24(4): 403-9, 2010 Apr.
Article in English | MEDLINE | ID: mdl-19778361

ABSTRACT

BACKGROUND AND OBJECTIVES: Patients report well-being as they are treated with phototherapy. We investigated hormone parameters and psychological well-being after phototherapy in a placebo-controlled study. METHODS: A total of 77 patients with dermatological conditions and 22 healthy volunteers were divided into four groups. The patients received phototherapy either on the whole body or only on hands and/or feet. The volunteers were given either whole-body phototherapy or placebo light. Serum or plasma samples were analysed for cortisol, calcium, magnesium, phosphate, TSH, T(4), T(3) and 25-hydroxyvitamin D, and urine samples for cortisol. Patients and volunteers answered a questionnaire before and 6 weeks after phototherapy/placebo light. Psychiatric ratings were performed according to the Comprehensive Psychopathological Self-rating Scale for Affective Syndromes, a self-report version of which has been transformed to correspond to the Montgomery-Asberg Depression Rating Scale (MADRS). RESULTS: In the patients who received whole-body irradiation, we observed a significant improvement in both MADRS score and cognitive-symptom score after the completion of phototherapy. We also observed a significantly higher level of 25-hydroxyvitamin D after phototherapy, but no difference in the other hormone parameters. CONCLUSION: Whole-body phototherapy of patients with dermatological conditions results in improved well-being and significantly higher levels of 25-hydroxyvitamin D in serum.


Subject(s)
Hormones/blood , Skin Diseases/psychology , Skin Diseases/radiotherapy , Ultraviolet Therapy/methods , Ultraviolet Therapy/psychology , Adult , Affect , Foot , Hand , Humans , Hydrocortisone/blood , Middle Aged , PUVA Therapy/methods , PUVA Therapy/psychology , Placebos , Psychological Tests , Surveys and Questionnaires , Thyroxine/blood , Triiodothyronine/blood , Vitamin D/analogs & derivatives , Vitamin D/blood , Whole-Body Irradiation/methods , Whole-Body Irradiation/psychology
3.
Br J Dermatol ; 146(2): 285-9, 2002 Feb.
Article in English | MEDLINE | ID: mdl-11903241

ABSTRACT

BACKGROUND: Port-wine stains (PWS) are congenital vascular malformations occurring in 0.3% of children. The pulsed dye laser is a well established treatment for PWS. OBJECTIVES: To compare, clinically and histologically, the effects of the flashlamp pulsed dye laser with the argon-pumped dye laser in the treatment of PWS. METHODS: Thirty patients were treated on two to four test areas with both laser types using different energy fluences. A flashlamp pulsed dye laser with 0.45 ms pulse duration and a spot size of 5 mm was compared with an argon-pumped dye laser, with a spot size of 1 mm delivered with a robotic scanning laser handpiece (Hexascan) and 70-190 ms pulse duration. Both were tuned to 585 nm. Twelve weeks later the degree of lightening was evaluated and biopsies were taken. To count the vessels the skin sections were stained with CD34 using an immunohistochemical technique. The vessels were divided into three groups by diameter (d): d < 10 microm, 10 < or = d < 20 microm, d > or = 20 microm. RESULTS: The clinical results showed a significantly better lightening using the flashlamp pulsed dye laser than with the argon-pumped dye laser. The histological results showed a significant decrease in the number of vessels of diameter larger than 20 microm in treated compared with untreated lesions. We found no histological difference in the number of vessels between the two laser treatments. However, there was a tendency towards more small vessels (diameter < 10 microm) after one treatment with the flashlamp pulsed dye laser compared with untreated PWS. CONCLUSIONS: The flashlamp pulsed dye laser is clinically superior to the argon-pumped dye laser in the treatment of PWS.


Subject(s)
Laser Therapy/instrumentation , Port-Wine Stain/surgery , Adolescent , Adult , Female , Follow-Up Studies , Humans , Laser Therapy/adverse effects , Laser Therapy/methods , Male , Middle Aged , Port-Wine Stain/pathology , Skin Pigmentation , Treatment Outcome
4.
Acta Derm Venereol ; 81(3): 184-8, 2001.
Article in English | MEDLINE | ID: mdl-11558874

ABSTRACT

There is no curative treatment for mycosis fungoides (MF), the most common primary cutaneous T-cell lymphoma. The aim of this study was to investigate the response of single lesions to photodynamic therapy (PDT). The study included 10 plaque MF lesions and 2 tumour MF lesions from 10 patients. First, 20% 5-aminolevulinic acid was applied topically to the lesion and adjacent skin for 5-6 h. The lesion was then exposed to red light at around 630nm. Skin biopsies were taken before treatment, after clinical improvement and after clinical remission. The expression of CD3, CD4, CD7, CD8, CD1a, CD34, CD68, CD71, Ki-67, bcl-2 and p53 was studied immunohistochemically. There was complete clinical clearance in seven of nine plaque lesions. Neither tumour lesion responded to PDT. The biopsies confirmed a regression of the infiltrate after treatment. In the sparse remaining infiltrate a few CD4+ and CD8+ cells were found, most of which showed normal bcl-2. There were also fewer proliferating cells, illustrated by a decrease in Ki-67 and CD71. In conclusion, PDT has good clinical and histological effects in treating local plaque MF lesions.


Subject(s)
Aminolevulinic Acid/administration & dosage , Mycosis Fungoides/drug therapy , Photochemotherapy , Photosensitizing Agents/administration & dosage , Skin Neoplasms/drug therapy , Administration, Topical , Aged , Aged, 80 and over , Antigens, CD/analysis , Antigens, Neoplasm/analysis , Female , Humans , Immunohistochemistry , Ki-67 Antigen/analysis , Male , Middle Aged , Mycosis Fungoides/chemistry , Mycosis Fungoides/pathology , Skin Neoplasms/chemistry , Skin Neoplasms/pathology
5.
Photodermatol Photoimmunol Photomed ; 17(2): 66-70, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11338404

ABSTRACT

BACKGROUND: Ultraviolet radiation (UVR) has a variety of effects on human skin. Best known are the effects of UVB (290-320 nm) and UVA2 (320-340 nm), which cause DNA damage and increased risk of cancer. However, the effects of UVA1 (340-400 nm) have been not completely investigated. METHODS: The effects of repetitive low doses of UVA1 and visible light were studied in 12 healthy individuals. A part of the buttock was exposed to 20 J/cm2 UVA1 and another part of 126 J/cm2 of visible light three times a week for 4 weeks. Repeated punch biopsies were taken during the 4 weeks of treatment and also 2 weeks after the last irradiation. The avidin-biotin-immunoperoxidase technique was used to investigate the expression of p53, p21WAF, bcl-2, Ki67 and cyclin A. RESULTS: By comparison to untreated skin, an increased expression of p53 but not p21WAF in keratinocytes was seen. The bcl-2 protein expression increased slightly after both UVA1 and visible light. An increased staining with Ki67 and cyclin A after UVA1 but not after visible light was observed as a sign of increased proliferation. CONCLUSION: These results suggest that suberythemal doses of UVA1 and even visible light may cause DNA damage.


Subject(s)
Light , Skin/radiation effects , Ultraviolet Rays , Adult , Cyclin A/analysis , Cyclin-Dependent Kinase Inhibitor p21 , Cyclins/analysis , Female , Humans , Immunohistochemistry , Ki-67 Antigen/analysis , Male , Middle Aged , Proto-Oncogene Proteins c-bcl-2/analysis , Skin/chemistry , Tumor Suppressor Protein p53/analysis
6.
Br J Dermatol ; 136(3): 360-3, 1997 Mar.
Article in English | MEDLINE | ID: mdl-9115916

ABSTRACT

The standard wavelength in the treatment of port-wine stains (PWS) with the pulsed dye laser is 585 nm. In many cases, the response to therapy is not adequate despite many treatments, depending partly on vessels out of reach of the laser. Longer wavelengths penetrate deeper into the dermis, but are absorbed less by oxyhaemoglobin, and require higher fluences. In this study, 22 patients with PWS were treated with the flashlamp-pumped pulsed dye laser using two different wavelengths, 585 and 600 nm. Four adjacent sites with PWS were treated on one occasion with 585 nm, 600 nm and equal fluence, and with 1.5 and 2 times the 585 nm fluence. The test areas were examined blindly, by four evaluators, an average of 12.5 weeks later. There was significantly less lightening with 600 nm than with 585 nm (P < or = 0.001) when equal fluences were used. When 1.5 and 2 times the 585 nm fluence were applied, with 600 nm the lightening was equal to that after 585 nm. However, in individual cases (11 of 22) 600 nm showed a superior lightening of at least 20% compared to 585 nm. There was slight hyperpigmentation and hypopigmentation, but no atrophy or scarring. In conclusion, 585 nm remains the wavelength of choice in treatment of PWS with the pulsed dye laser. However, in cases that do not respond satisfactorily with 585 nm, it may be worth trying 600 nm with a fluence that is at least 1.5-2 times the 585 nm fluence.


Subject(s)
Dermatologic Surgical Procedures , Laser Therapy , Port-Wine Stain/surgery , Adolescent , Adult , Analysis of Variance , Female , Humans , Male , Middle Aged , Treatment Outcome
7.
Article in English | MEDLINE | ID: mdl-9361130

ABSTRACT

Solar urticaria is characterized by itching weals that occur a few minutes after exposure to visible or ultraviolet light. The symptoms may sometimes restrict normal daily life. Treatment is difficult in more severe cases. We describe one patient with solar urticaria who was successfully treated with cyclosporin A. The patient had first been treated with antihistamine, PUVA and chloroquine phosphate without effect. Cyclosporin was given in a dose of 4.5 mg/kg body weight/day. Phototesting before, during and after treatment showed a decreased light sensitivity to UVA, UVB and visible light during cyclosporin treatment compared with phototesting before therapy. The patient could be out in the sun for at least 1 h with minimal urticaria during cyclosporin therapy compared with only a few minutes previously. However, 1-2 weeks after cyclosporin therapy was discontinued, skin symptoms returned. Cyclosporin therapy is a possible treatment in severe cases of solar urticaria where other treatments have failed, especially in countries where treatment is necessary only for a few months during summer.


Subject(s)
Cyclosporine/therapeutic use , Immunosuppressive Agents/therapeutic use , Photosensitivity Disorders/drug therapy , Sunlight/adverse effects , Urticaria/drug therapy , Adult , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Chloroquine/analogs & derivatives , Chloroquine/therapeutic use , Cyclosporine/administration & dosage , Female , Histamine H1 Antagonists/therapeutic use , Humans , Immunosuppressive Agents/administration & dosage , Light/adverse effects , PUVA Therapy , Photosensitivity Disorders/etiology , Recurrence , Skin Tests , Time Factors , Treatment Outcome , Ultraviolet Rays/adverse effects , Urticaria/etiology
SELECTION OF CITATIONS
SEARCH DETAIL
...